Dose reduction (DR) of biologics, where possible, seems promising for more efficient use of
expensive biologics. For implementation of DR strategies, it is essential to get insight in …

Dose reduction of biologics for psoriasis could contribute to more efficient use of these
expensive medicines. Evidence on opinions of patients with psoriasis regarding dose …

Importance Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed
dose, but lower doses might be possible. Objective To investigate whether dose reduction …

Background Dose reduction of biologics for psoriasis is applied in daily practice, although
guidelines are lacking. Striving for clear criteria is important, as it leads to a consistent …

Introduction Despite the large routine use of biologic drugs in psoriasis treatment, the
majority of studies do not take into consideration dose‐adjustment practice in 'real …

Background To date, evidence on the dose adjustments of biologics in the real‐world
treatment of psoriasis is limited. However, dose adjustments may have important clinical and …

Introduction In biologic therapy, dose modification in carefully selected patients when
psoriasis is in remission could reduce treatment costs and the risks associated with drug …

Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors
(i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The …

Background Psoriasis is a chronic inflammatory disease affecting~ 2–3% of the Australasian
population. Therapeutic options include topical agents, phototherapy, systemic …

Background Therapeutic drug monitoring (TDM) may lead to more rational use of biologics.
Still, TDM is largely underexplored in psoriasis. Little is known about the dosing behavior of …